Online citations, reference lists, and bibliographies.
← Back to Search

Central Nervous System Metastases In Women Who Receive Trastuzumab‐based Therapy For Metastatic Breast Carcinoma

J. Bendell, S. Domchek, H. Burstein, L. Harris, J. Younger, I. Kuter, C. Bunnell, M. Rué, R. Gelman, E. Winer
Published 2003 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Women with HER‐2 overexpressing metastatic breast carcinoma benefit from trastuzumab‐based therapy, but trastuzumab does not cross the blood‐brain barrier. The authors characterized central nervous system (CNS) disease in these women.
This paper references
10.1212/WNL.9.2.91
Experiences with metastatic neoplasms involving the spinal cord
K. Barron (1959)
10.1200/JCO.2001.19.10.2722
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
H. Burstein (2001)
10.1200/JCO.2000.18.11.2349
Trastuzumab in CSF.
B. Pestalozzi (2000)
Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group.
S. Noga (1993)
10.1053/SRAO.2002.35251
Molecular prognostic factors for breast cancer metastasis and survival.
F. Esteva (2002)
10.1093/ANNONC/MDG300
Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival.
K. Miller (2003)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1200/JCO.1996.14.3.737
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
J. Baselga (1996)
A report of a case and review of the literature
Milton J. Koch (1976)
Leptomeningeal spread of breast
V Sondak
High incidence of brain metastases (BM) in patients on trastuzumab (H) for advanced breast cancer [abstract
R Eitzen (2002)
10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B
Central nervous system metastasis from breast carcinoma autopsy study
Y. Tsukada (1983)
The incidence of brain metastases in HER2/neuϩ stage IV breast cancer patients
R K Lai
10.1002/1097-0142(197911)44:5<1913::AID-CNCR2820440554>3.0.CO;2-D
The natural history of breast cancer patients with brain metastases
A. Distefano (1979)
10.1002/JSO.2930230311
Breast carcinoma: Pattern of metastasis at autopsy
Y. Lee (1983)
High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer center
A M Wardley
10.1016/S0093-7754(01)90190-3
The platinum agents: a role in breast cancer treatment?
J. Crown (2001)
Breast carcinoma: pattern of metastatic spread at autopsy
Y. Lee (1983)
High incidence of brain metastases (BM) in patients on trastuzumab (H) for advanced breast cancer
R Eitzen
10.1200/JCO.2002.07.058
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
F. Esteva (2002)
Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2 overexpressing (HER2ϩ) metastatic breast cancer (MBC)
L Norton
10.1002/1097-0142(19810715)48:2<395::AID-CNCR2820480228>3.0.CO;2-1
Leptomeningeal spread of breast cancer: Report of case and review of the literature
V. Sondak (1981)
10.1023/A:1006486423827
Radiation therapy in the management of brain metastases from breast cancer
T. Fokstuen (2004)
Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene
DJ Slamon (1987)
10.1200/JCO.1999.17.9.2639
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
M. Cobleigh (1999)
Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status.
D. Maki (2000)
[METASTATIC TUMORS OF THE CENTRAL NERVOUS SYSTEM].
A. R. DE MELLO (1963)
High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer center [abstract
AM Wardley (2002)
The incidence of brain metastases in HER2/neu stage IV breast cancer patients [abstract
RK Lai (2001)
10.1200/JCO.1998.16.8.2659
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
M. Pegram (1998)
10.1038/sj.onc.1201331
HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer
C. Benz (1997)
Phase II study of weekly intravenous recombinant humanized anti-p 185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer
J Baselga (1996)
10.1097/00005072-197809000-00183
METASTATIC TUMORS IN THE CENTRAL NERVOUS SYSTEM
S. Hojo (1978)



This paper is referenced by
10.1038/ncponc0487
Does trastuzumab increase the risk of isolated central nervous system metastases in patients with breast cancer?
R. Weil (2006)
10.1097/01.pas.0000213306.05811.b9
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR
D. Hicks (2006)
10.1007/s00761-009-1648-6
Behandlung der Patientinnen mit HER2- (ErbB2-) positivem Mammakarzinom
Michael Untch (2009)
10.1016/j.ccr.2009.01.027
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
Marta Páez-Ribes (2009)
Cancer Therapy : Preclinical Pazopanib Reveals a Role for Tumor Cell B-Raf in the Prevention of HER 2 þ Breast Cancer Brain Metastasis
B. Gril (2010)
Application de la technique CellSearch® Veridex pour la détection de cellules tumorales dans les liquides biologiques chez les patients atteints de cancers
Qian Tu (2015)
10.1158/1078-0432.CCR-05-1793
Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
K. Kim (2006)
10.1007/s11910-014-0518-9
Systemic Therapy of Brain Metastases
H. Brastianos (2014)
10.1007/s10549-018-4852-5
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases
Amanda E. D. Van Swearingen (2018)
10.1001/jamaoncol.2017.0001
Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study
A. Martin (2017)
10.1016/S1470-2045(13)70017-2
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
B. Pestalozzi (2013)
10.2325/JBCS.14.420
Brain metastases after achieving local pathological complete responses with neoadjuvant chemotherapy
S. Tsukamoto (2007)
10.3109/00207451003743631
Dural Metastatic Cancer From Primary Breast Carcinoma
Beamon Agarwal (2010)
10.1158/1078-0432.CCR-06-2659
The Biology of Metastasis to a Sanctuary Site
D. Palmieri (2007)
Pharmacological Targeting of a Metabolic Co-Dependency Pathway in Brain Cancers
Genaro R. Villa (2016)
10.1586/14737140.7.11.1561
CNS metastasis in primary breast cancer
M. Sharma (2007)
10.1007/s11864-013-0248-2
Molecular Subtyping of Brain Metastases and Implications for Therapy
J. Renfrow (2013)
10.1080/14737159.2018.1439382
The breast tumor microenvironment: role in cancer development, progression and response to therapy
Suruchi Mittal (2018)
10.1007/978-1-4939-1145-5_30
Management of Metastatic Breast Cancer
Sarah Keck (2015)
10.1586/era.10.86
Diagnosis and individualized therapy of neoplastic meningitis
H. Strik (2010)
10.1007/s10555-016-9638-9
Advances in decoding breast cancer brain metastasis
C. Zhang (2016)
10.5772/INTECHOPEN.86047
Innovations in Metastatic Brain Tumor Treatment
Caleb Stewart (2019)
10.1093/annonc/mdq239
Incidence of and survival following brain metastases among women with inflammatory breast cancer.
S. Dawood (2010)
10.1016/j.ctrv.2009.06.002
Lapatinib: a competitor or companion to trastuzumab?
D. Collins (2009)
10.1016/j.pharmthera.2016.10.011
Treatment of brain metastases in the modern genomic era
I. Dagogo-Jack (2017)
10.7759/CUREUS.43
Gamma Knife Radiosurgery for Breast Cancer Metastases to the Brain: Outcomes and Prognostic Factors from a Large Prospectively Collected Database
A. Wolf (2012)
Targeting HER2 in brain metastases from breast cancer.
D. Kirsch (2003)
10.1007/s10549-004-0999-3
Central nervous system metastases in women after multimodality therapy for high risk breast cancer
L. Carey (2004)
10.1007/3-540-31303-6_65
Epidurale spinale Metastasen und leptomeningeale Karzinose
S. Hofer (2006)
10.1016/J.CLON.2006.07.006
The incidence and treatment outcome after radiotherapy for brain metastases in HER-2-positive metastatic breast cancer patients treated with trastuzumab.
S. Arif (2006)
10.1158/1078-0432.CCR-06-2095
Treatment of Single Brain Metastasis with Resection, Intracavity Carmustine Polymer Wafers, and Radiation Therapy Is Safe and Provides Excellent Local Control
M. Ewend (2007)
10.1016/S1043-321X(07)80221-9
Primary Breast Cancer Phenotypes Associated With Propensity for Central Nervous System Metastases
N. Lin (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar